CN104474255A - Traditional Chinese medicine composition for treating diabetic retinopathy and preparation method of traditional Chinese medicine composition - Google Patents
Traditional Chinese medicine composition for treating diabetic retinopathy and preparation method of traditional Chinese medicine composition Download PDFInfo
- Publication number
- CN104474255A CN104474255A CN201410760397.4A CN201410760397A CN104474255A CN 104474255 A CN104474255 A CN 104474255A CN 201410760397 A CN201410760397 A CN 201410760397A CN 104474255 A CN104474255 A CN 104474255A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- traditional chinese
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title abstract description 19
- 206010012689 Diabetic retinopathy Diseases 0.000 title abstract description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 9
- 235000008434 ginseng Nutrition 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 206010012601 diabetes mellitus Diseases 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 16
- 239000012567 medical material Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 13
- 208000017442 Retinal disease Diseases 0.000 claims description 9
- 206010038923 Retinopathy Diseases 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 241000208340 Araliaceae Species 0.000 claims description 8
- 239000009636 Huang Qi Substances 0.000 claims description 8
- 239000012467 final product Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000007547 defect Effects 0.000 abstract description 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 241000037740 Coptis chinensis Species 0.000 abstract 1
- 244000111489 Gardenia augusta Species 0.000 abstract 1
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 206010019851 Hepatotoxicity Diseases 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 241001522232 Pinellia ternata Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 230000007686 hepatotoxicity Effects 0.000 abstract 1
- 231100000304 hepatotoxicity Toxicity 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 16
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 230000002207 retinal effect Effects 0.000 description 11
- 210000001525 retina Anatomy 0.000 description 10
- 206010038491 Renal papillary necrosis Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002647 laser therapy Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000004281 retinal morphology Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical class NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000003668 pericyte Anatomy 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical group O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 235000002687 Caesalpinia echinata Nutrition 0.000 description 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010063341 Metamorphopsia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 201000010183 Papilledema Diseases 0.000 description 1
- 241000127464 Paubrasilia echinata Species 0.000 description 1
- 206010038886 Retinal oedema Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 201000011195 retinal edema Diseases 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicines, relates to a traditional Chinese medicine composition and a preparation method thereof and particularly relates to a traditional Chinese medicine composition for treating diabetic retinopathy and a preparation method of the traditional Chinese medicine composition. Aiming at overcoming the defects of relatively high hepatotoxicity and poor curative effect of the current chemical drug for treating diabetic retinopathy in the prior art, the invention provides the traditional Chinese medicine composition for treating or preventing diabetic retinopathy, and the traditional Chinese medicine composition comprises the following components: 15 parts of astragalus, 15 parts of ginseng, 6 parts of ligusticum wallichii, 10 parts of cacumen platycladi, 10 parts of rhizoma alismatis, 6 parts of coptis chinensis, 8 parts of radix rehmanniae praeparata, 5 parts of radix ophiopogonis, 20 parts of rhizoma atractylodis macrocephalae, 12 parts of dandelion, 10 parts of pinellia ternata, 5 parts of cape jasmine, 5 parts of herba artemisiae scopariae and 10 parts of liquorice. The traditional Chinese medicine composition has a favorable curative effect on the aspect of treating or preventing diabetic retinopathy, low in side effect and remarkable in clinical popularization value.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to Chinese medicine composition of a kind for the treatment of of diabetic retinopathy change and preparation method thereof.
Background technology
Diabetic renal papillary necrosis is the consequence of diabetic microangiopathy, and because diabetes cause retinal capillary wall to damage, blood is hypercoagulability in addition, easily causes thrombosis and blood stasis, even angiorrhexis.At present, the retinopathy that diabetes cause causes VI and blind main cause.This disease morbidity early stage patient is without any sensation, if make regular check on optical fundus, doctor can see whether your optical fundus changes, and is at this moment the best opportunity of prevention.Mid-term there will be retinal edema, and eye may occur new vessels and hemorrhage to vitreous chamber.Now can feel blurred vision, have shadow to wave at the moment, metamorphopsia etc.During late period, vitreous hemorrhage is serious, retina shedding, even blind.
Mainly there are laser therapy and Drug therapy two kinds of modes in the retinopathy caused for diabetes clinically at present. and wherein retinal laser therapy is the basic means that treatment of diabetic retinopathy becomes, directly can solidify closed new vessels, microangioma and have the blood capillary of fluorescence leakage, laser therapy makes part retinal tissue by laser photocoagulation, remaining retina can obtain abundanter blood oxygen supply, blocking-up new vessels produces, thus stops the development of retinopathy.But this treatment means only can play retarding action for diabetic retinopathy, the treatment situation for conditions of patients is poor, and medical expense is high, and patient is difficult to bear.The incidence rate that Drug therapy effectively can reduce diabetic ocular fundus diseases is carried out for diabetics, and Drug therapy also can play direct therapeutical effect to diabetic retinopathy usually.Western medicine effectively cannot treat diabetic ophthalmopathy, and long-term taking Western medicine has more side effect, Chinese medicine curative effect in treatment is better, the symptom such as vitreous hemorrhage, macular edema caused for diabetes when having had at present the treatment of multiple Chinese medicine preparation such as peace snow granule, sugared net soup, discharge opeing soup for diabetic retinopathy has must mitigation, but still it is not satisfied to there is therapeutic effect, the defect that relapse rate is high.Therefore, still there is very large demand for effective medicine of diabetic ophthalmopathy in medical care patient.The present invention, namely from pathogeny and the clinical symptoms of diabetic ophthalmopathy, provides that a kind of particularly diabetic retinopathy can treating both the principal and secondary aspects of a disease to diabetic retinopathy, the medicine that relapse rate is low.
Summary of the invention
For the deficiency of current diabetic renal papillary necrosis clinical treatment medicine, first object of the present invention is the Chinese medicine composition providing a kind for the treatment of of diabetic retinopathy to become, this Chinese medicine composition has the treatment advantage that therapeutic effect is remarkable, side effect is little, permanence operation is good when treatment of diabetic retinopathy becomes, have fine medical application prospect.Chinese medicine composition of the present invention, according to components by weight percent meter, it obtains primarily of the raw material of following weight portion: the Radix Astragali 15 parts, Radix Ginseng 15 parts, Rhizoma Chuanxiong 6 parts, Cacumen Platycladi 10 parts, Rhizoma Alismatis 10 parts, Rhizoma Coptidis 6 parts, 8 parts, Radix Rehmanniae Preparata, Radix Ophiopogonis 5 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Herba Taraxaci 12 parts, the Rhizoma Pinelliae 10 parts, Fructus Gardeniae 5 parts, Herba Artemisiae Scopariae 5 parts, 10 parts, Radix Glycyrrhizae.
In Chinese medicine composition described above, various Chinese medicinal components is all got its conventional agents area and is used as medicine.The mutual compatible combination of said medicine in the present invention, complements one another, and reaches the object of blood sugar lowering, antiinflammatory, liver heat removing and eyesight improving, has good curative effect to diabetic renal papillary necrosis.
Fructus Lycii 6 parts, Herba Ecliptae 12 parts, the Radix Paeoniae Alba 8 parts can also be contained in the present invention's Chinese medicine composition described above.Fructus Lycii, Herba Ecliptae, the Radix Paeoniae Alba three kinds of medicines are used in conjunction, and not only significantly can improve the microangiopathies situation of patient, and three kinds of medicines and aforementioned pharmaceutical compositions coupling of the present invention can strengthen its therapeutic effect to diabetic renal papillary necrosis further.
The method preparing Chinese medicine composition of the present invention is as follows: each medical material getting above-mentioned components by weight percent, adds the 5-15 water doubly of medical material gross weight, soaks 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.05-1.25, and this relative density is testing result at 60 c, and adding ethanol to alcohol content is 60-90%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, to obtain final product.The above-mentioned Chinese medicine composition of the present invention can be prepared into pharmaceutical preparation conventional clinically further, is preferably mixture, tablet, capsule.
The present invention also discloses a kind of purposes of above-mentioned Chinese medicine composition, and namely above-mentioned Chinese medicine composition is in the purposes preparing treatment or prevent diabetes in retinopathy medicine.By pharmacodynamic experiment, the present invention confirms that Chinese medicine composition causes rat diabetes retinopathy for streptozotocin and has good therapeutic effect.Compare with model group, Chinese medicine composition high and low dose group and positive group all can reduce EB value (P<0.05), obvious reduction E/P(P<0.01), and can retinal morphology be recovered, Chinese medicine composition high and low dose group also obviously can reduce retinal tissue MDA value, raise its SOD value (P<0.01), and positive group little on the impact of SOD and MDA.
In a word, the present invention compared with prior art, have the activity that fine treatment of diabetic retinopathy becomes, and the present invention is pure Chinese medicinal preparation, to human body particularly to liver avirulence.When the present invention uses as diabetic renal papillary necrosis medicine, drug effect is comprehensive, while blood sugar lowering antiinflammatory, liver heat removing and eyesight improving, effect of activating blood circulation to dissipate blood stasis, dispelling phlegm and eliminating dampness can also be obtained, the mutual compatible combination of ladies and gentlemen's medicine, complements one another, and plays synergism, the object strengthening immunologic function can be reached, and Chinese medicine composition preparation of the present invention is simple, and substantially nontoxic, raw material is easy to get, be suitable for popular use, there is good application prospect.
Detailed description of the invention
Further describe the present invention below by way of detailed description of the invention, but the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, Chinese medicine composition of the present invention is suitably improved, replaces the identical component of effect, will become apparent to those skilled in the art that they are all deemed to be included within scope of the present invention.
part I, the preparation of Chinese medicine composition of the present invention
embodiment 1 Chinese medicine composition mixture of the present invention
Prescription: the Radix Astragali 15 parts, Radix Ginseng 15 parts, Rhizoma Chuanxiong 6 parts, Cacumen Platycladi 10 parts, Rhizoma Alismatis 10 parts, Rhizoma Coptidis 6 parts, 8 parts, Radix Rehmanniae Preparata, Radix Ophiopogonis 5 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Herba Taraxaci 12 parts, the Rhizoma Pinelliae 10 parts, Fructus Gardeniae 5 parts, Herba Artemisiae Scopariae 5 parts, 10 parts, Radix Glycyrrhizae.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 5 times of medical material gross weight, soaks 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.1, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 75%(v/v), leave standstill 24 hours, get supernatant, recovery ethanol concentrates, and adds water to 1000ml, stirs evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
embodiment 2 Chinese medicine composition mixture of the present invention
Prescription: the Radix Astragali 15 parts, Radix Ginseng 15 parts, Rhizoma Chuanxiong 6 parts, Cacumen Platycladi 10 parts, Rhizoma Alismatis 10 parts, Rhizoma Coptidis 6 parts, 8 parts, Radix Rehmanniae Preparata, Radix Ophiopogonis 5 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Herba Taraxaci 12 parts, the Rhizoma Pinelliae 10 parts, Fructus Gardeniae 5 parts, Herba Artemisiae Scopariae 5 parts, Radix Glycyrrhizae 10 parts of Fructus Lycii 6 parts, Herba Ecliptae 12 portions of Radix Paeoniae Albas 8 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 5 times of medical material gross weight, soaks 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.1, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 75%(v/v), leave standstill 24 hours, get supernatant, recovery ethanol concentrates, and adds water to 1000ml, stirs evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
embodiment 3 Chinese medicine composition tablet of the present invention
Prescription: the Radix Astragali 15 parts, Radix Ginseng 15 parts, Rhizoma Chuanxiong 6 parts, Cacumen Platycladi 10 parts, Rhizoma Alismatis 10 parts, Rhizoma Coptidis 6 parts, 8 parts, Radix Rehmanniae Preparata, Radix Ophiopogonis 5 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Herba Taraxaci 12 parts, the Rhizoma Pinelliae 10 parts, Fructus Gardeniae 5 parts, Herba Artemisiae Scopariae 5 parts, 10 parts, Radix Glycyrrhizae.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 10 times of medical material gross weight, soaks 60 minutes, decoct 1 time, each 1 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.25, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 80%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulation, tabletting and get final product.
embodiment 4 Chinese medicine composition tablet of the present invention
Prescription: the Radix Astragali 15 parts, Radix Ginseng 15 parts, Rhizoma Chuanxiong 6 parts, Cacumen Platycladi 10 parts, Rhizoma Alismatis 10 parts, Rhizoma Coptidis 6 parts, 8 parts, Radix Rehmanniae Preparata, Radix Ophiopogonis 5 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Herba Taraxaci 12 parts, the Rhizoma Pinelliae 10 parts, Fructus Gardeniae 5 parts, Herba Artemisiae Scopariae 5 parts, Radix Glycyrrhizae 10 parts of Fructus Lycii 6 parts, Herba Ecliptae 12 portions of Radix Paeoniae Albas 8 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 10 times of medical material gross weight, soaks 60 minutes, decoct 1 time, each 1 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.25, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 80%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulation, tabletting and get final product.
embodiment 5 Chinese medicinal composition capsules agent of the present invention
Prescription: the Radix Astragali 15 parts, Radix Ginseng 15 parts, Rhizoma Chuanxiong 6 parts, Cacumen Platycladi 10 parts, Rhizoma Alismatis 10 parts, Rhizoma Coptidis 6 parts, 8 parts, Radix Rehmanniae Preparata, Radix Ophiopogonis 5 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Herba Taraxaci 12 parts, the Rhizoma Pinelliae 10 parts, Fructus Gardeniae 5 parts, Herba Artemisiae Scopariae 5 parts, 10 parts, Radix Glycyrrhizae.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 8 times of medical material gross weight, soaks 45 minutes, decoct 4 times, each 1.5 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.2, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 90%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated and get final product.
embodiment 6 Chinese medicinal composition capsules agent of the present invention
Prescription: the Radix Astragali 15 parts, Radix Ginseng 15 parts, Rhizoma Chuanxiong 6 parts, Cacumen Platycladi 10 parts, Rhizoma Alismatis 10 parts, Rhizoma Coptidis 6 parts, 8 parts, Radix Rehmanniae Preparata, Radix Ophiopogonis 5 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Herba Taraxaci 12 parts, the Rhizoma Pinelliae 10 parts, Fructus Gardeniae 5 parts, Herba Artemisiae Scopariae 5 parts, Radix Glycyrrhizae 10 parts of Fructus Lycii 6 parts, Herba Ecliptae 12 portions of Radix Paeoniae Albas 8 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 8 times of medical material gross weight, soaks 45 minutes, decoct 4 times, each 1.5 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.2, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 90%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated and get final product.
part II, the pharmacodynamics of Chinese medicine composition of the present invention is investigated
embodiment 7 Chinese medicine composition composition oral preparation causes the effect of rat diabetes retinopathy to streptozotocin
1 animal grouping and modeling
SD rat 150, after adaptability raises one week, wherein normally feeds for 10 as a control group, after all the other Rat Fast 12h, prepares diabetes model by 50mg/kg left lower quadrant intracavitary administration 2% streptozotocin (STZ) solution.Streptozotocin solution is in configuring with 0.1mmol/L, pH4.5 citrate buffer solution before use.Matched group injects isodose citric acid, sodium citrate buffer solution.Detect the non-fasting glucose of rat tail vein after injection 72h, blood glucose value >=16.7mmol/L is defined as diabetes rat.Grouping and administration: modeling starts to calculate the course of disease after one week and starts administration.Get into mould rat 100 and be only divided into 5 groups at random by body weight, blood sugar level: Chinese medicine composition object height, in and low dose group, model group (normal saline), positive group.Each group all by dosage gastric infusion in table 1, every day 1 time, successive administration 4 weeks.Survey rat body weight weekly, to determine dosage.
2 testing indexs and assay method
2.1 Evans blue tracer quantitative assay retinal blood vessels leak amounts
Often group gets 6 rats, after anesthesia, EB liquid is slowly injected through tail vein by 45mg/kg dosage, can be observed large rathole and whole skin and become blue instantaneously, circulate after 120 minutes, open thoracic cavity and expose heart, mosquito forceps clamping postcava, by the capable left ventricle perfusion of ventricles liquid being preheated to 37 DEG C, cut off right auricle simultaneously, perfusion pressure 120mmHg (about 164cmH20), perfusion continues 3 minutes, to remove endovascular EB.After perfusion terminates, take out eyeball immediately, careful separation goes out retina, spends the night to dry and weighs.Retina and 150 μ L Methanamides are hatched 18 hours at 70 DEG C, then extract are moved in centrifuge tube, centrifuge at 4 DEG C, centrifugal 90min under 6000rpm/min.Get supernatant 100 μ L microplate reader and survey its absorbance (A) value, measure the absorption photometric value under 620nm and 740nm two kinds of wavelength respectively, get two value differences and the clean absorption photometric value final absorbance as sample.Each sample measures 3 times, and 5 seconds, interval, finally gets its meansigma methods, then tries to achieve EB concentration in sample according to EB standard solution absorbance difference in Methanamide.With retina dry weight (mg) standardization EB (ng) content, result is expressed as: ng/mg.
2.2 Biochemical Indexes and retinal morphology are observed
2.2.1 sample collection
After last administration, each group Rat Fast water 12h, measures blood glucose value, then etherization, vacuum test tube Culling heart blood, separation of serum; Extract rat eye, left eye is placed in 10% formalin solution and is fixed for retinal microvasculopathy reason and morphological observation, and right eye is blunt separation retina under condition of ice bath immediately, for detecting SOD activity, MDA content.
2.2.2 retinal tissue section and observation
Immunohistochemistry is observed: the formaldehyde eyeball taken off being placed in 10% is fixed on fixes 48h, removing anterior ocular segment is that eyecup is cut into three pieces by Fructus Citri tangerinae lobe sample, isolate retina, running water 24h, put into 3% trypsin solution of the Tris-HCl buffer solution with 0.1ml/L, pH7.8,37 DEG C of water bath with thermostatic control 80min, when after retinal tissue protein dissolution, retina is moved in water, vibrate gently, until the retinal blood pipe network of remaining layer of transparent, move on microscope slide, natural drying, PAS adds brazilwood extract dyeing.The retinal capillary morphological change of observation by light microscope rat, adopt computerized image analysis sgstem quantitative analysis, to the blood capillary of every routine retina digestion specimen, count the endotheliocyte in 5 visuals field and pericyte, calculate the ratio (E/P) of endotheliocyte and pericyte.
3 statistical analysis
Experimental data represents with mean ± S.D., adopts SPSS software, and statistical test uses t inspection and single factor test F in groups to check, test level α=0.05.
4, result of the test and analysis
Chinese medicine composition composition oral preparation on the impact of rat diabetes retinopathy, macular edema in table 1, table 2.To make in retinal tissue after rat modeling success that SOD vigor reduces, MDA content and E/P raise and there is the rising of EB value, there is the phenomenons such as edema is hemorrhage in retina, model group has significant difference compared with normal group.Compare with model group, Chinese medicine composition high and low dose group and positive group all can reduce EB value (P<0.05), obvious reduction E/P(P<0.01), and can retinal morphology be recovered, Chinese medicine composition high and low dose group also obviously can reduce retinal tissue MDA value, raise its SOD value (P<0.01), and positive group little on the impact of SOD and MDA.
Table 1 Chinese medicine composition composition oral preparation is on the impact of rat diabetes retinopathy
Compare with model group,
*p < 0.05,
*p < 0.01; Compared with positive controls,
#p < 0.05;
##p < 0.01
Compared with breviscapine group,
▲p < 0.05,
▲ ▲p < 0.01;
Table 2 Chinese medicine composition composition oral preparation is on the impact of diabetic renal papillary necrosis rat SOD, MDA and E/P
Compare with model group,
*p < 0.05,
*p < 0.01; Compared with positive controls,
#p < 0.05;
##p < 0.01
Compared with breviscapine group,
▲p < 0.05,
▲ ▲p < 0.01.
Claims (5)
1. a Chinese medicine composition, it is characterized in that it obtains primarily of the raw material of following weight portion: the Radix Astragali 15 parts, Radix Ginseng 15 parts, Rhizoma Chuanxiong 6 parts, Cacumen Platycladi 10 parts, Rhizoma Alismatis 10 parts, Rhizoma Coptidis 6 parts, 8 parts, Radix Rehmanniae Preparata, Radix Ophiopogonis 5 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Herba Taraxaci 12 parts, the Rhizoma Pinelliae 10 parts, Fructus Gardeniae 5 parts, Herba Artemisiae Scopariae 5 parts, 10 parts, Radix Glycyrrhizae.
2. Chinese medicine composition as claimed in claim 1, is characterized in that described Chinese medicine composition contains Fructus Lycii 6 parts, Herba Ecliptae 12 parts and the Radix Paeoniae Alba 8 parts.
3. Chinese medicine composition as claimed in claim 1 or 2, is characterized in that described Chinese medicine composition is mixture, tablet or capsule.
4. prepare the method for Chinese medicine composition as claimed in claim 1 or 2 for one kind, it is characterized in that it comprises the following steps: get each medical material, add the 5-15 water doubly of medical material gross weight, soak 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.05-1.25, this relative density is testing result at 60 c, adding ethanol to alcohol content is 60-90%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, to obtain final product.
5. Chinese medicine composition as claimed in claim 1 or 2 is in the purposes preparing treatment or prevent diabetes in retinopathy medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410760397.4A CN104474255A (en) | 2014-12-12 | 2014-12-12 | Traditional Chinese medicine composition for treating diabetic retinopathy and preparation method of traditional Chinese medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410760397.4A CN104474255A (en) | 2014-12-12 | 2014-12-12 | Traditional Chinese medicine composition for treating diabetic retinopathy and preparation method of traditional Chinese medicine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104474255A true CN104474255A (en) | 2015-04-01 |
Family
ID=52748956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410760397.4A Pending CN104474255A (en) | 2014-12-12 | 2014-12-12 | Traditional Chinese medicine composition for treating diabetic retinopathy and preparation method of traditional Chinese medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104474255A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105267632A (en) * | 2015-10-13 | 2016-01-27 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition composition treating diabetic macular edema |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1192914A (en) * | 1997-03-11 | 1998-09-16 | 孙松 | Fuming capsule and preparing method thereof |
| KR20140084928A (en) * | 2012-12-27 | 2014-07-07 | 한림대학교 산학협력단 | Composition for treating diabete and diabete-induced complication containing an extract from Agrimonia pilosa |
-
2014
- 2014-12-12 CN CN201410760397.4A patent/CN104474255A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1192914A (en) * | 1997-03-11 | 1998-09-16 | 孙松 | Fuming capsule and preparing method thereof |
| KR20140084928A (en) * | 2012-12-27 | 2014-07-07 | 한림대학교 산학협력단 | Composition for treating diabete and diabete-induced complication containing an extract from Agrimonia pilosa |
Non-Patent Citations (2)
| Title |
|---|
| 刘静: "中药治疗糖尿病性视网膜病变的临床观察", 《中医杂志》 * |
| 王纯庠等: "中医药治疗糖尿病视网膜病变回眸研究", 《中西医结合心脑血管病杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105267632A (en) * | 2015-10-13 | 2016-01-27 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition composition treating diabetic macular edema |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103099959B (en) | Traditional Chinese medicine preparation for treating ulcerative colitis and preparation method thereof | |
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
| CN103845418B (en) | A kind of Chinese medicine composition for the treatment of retinal hemorrhage and uses thereof | |
| CN1327876C (en) | Chinese drugs compositions for treating diabetes and its complications | |
| CN103223111B (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN103041208A (en) | Chinese herbal preparation for treating climacteric syndrome of women, and preparation method thereof | |
| CN103690784B (en) | The Chinese medicine composition for the treatment of Complicating with Hypentersion nephropathy and preparation method | |
| CN102885975B (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN104083640B (en) | Traditional Chinese medicinal composition for treating diabetes mellitus and preparation method thereof | |
| CN105412410A (en) | Traditional Chinese medicine preparation for preventing and treating radiographic contrast nephropathy | |
| CN104435487A (en) | Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof | |
| CN104491612A (en) | Purpose of traditional Chinese medicine composition in preparing medicament for treating diabetic retinopathy | |
| CN106237131A (en) | The Herba Taraxaci oral liquor of lowering blood-fat and reducing weight and oral liquid thereof | |
| CN105343593A (en) | Spica prunellae health oral liquid capable of decreasing blood pressure and blood lipid as well as preparation method of spica prunellae health oral liquid | |
| CN104689079A (en) | Traditional Chinese medicine composition for treating diabetic retinopathy and preparation method thereof | |
| CN105055785A (en) | Traditional Chinese medicine composition for treating diabetic retinopathy | |
| CN104922448A (en) | Traditional Chinese medicine composition for treating fundus hemorrhage and application thereof | |
| CN104474255A (en) | Traditional Chinese medicine composition for treating diabetic retinopathy and preparation method of traditional Chinese medicine composition | |
| CN105267632A (en) | Traditional Chinese medicine composition composition treating diabetic macular edema | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN109528865A (en) | It is a kind of for treating the Chinese materia medica preparation and preparation method thereof of person in middle and old age's ophthalmology disease | |
| CN104324139B (en) | A kind of pharmaceutical composition treating xerophthalmia | |
| CN104523962A (en) | Radix morindae officinalis health maintenance traditional Chinese medicine wine and preparation method | |
| CN103599477B (en) | A kind of Chinese medicine composition for treating humid-heat stagnation type chronic prostatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150401 |
|
| RJ01 | Rejection of invention patent application after publication |